| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
JNK3 (IC50 = 0.7 nM); JNK1 (IC50 = 1.5 nM); JNK2 (IC50 = 2 nM)
|
|---|---|
| ln Vitro |
JNK-IN-7 is a relatively selective JNK inhibitor in cells. JNK-IN-7 binds to IRAK1 (IC50 = 14.1 nM), YSK4 (IC50 = 4.8 nM), ERK3 (IC50 = 22 nM), PIK3C3, PIP5K3, and PIP4K2C in addition to JNK 1, 2, and 3[1]. It has been shown that TNF stimulation for 24 and 48 hours significantly reduces the expression of divalent metal-ion transporter 1 (DMT1) in HCT116, while JNK-IN-7 can significantly reverse the decrease. While JNK-IN-7 can significantly suppress this function, TNF can down-regulate DMT1 expression[2].
|
| Cell Assay |
In DMEM medium, intestinal epithelial cell line (HCT116) is cultured. JNK-IN-7 (1 μM), NF-κB inhibitor (BAY 11-7082, 1 μM), and caspase-3/8 inhibitor (Z-DEVD-FMK, 50 μM) are also added to the culture medium in order to identify the mechanisms of TNF involved in controlling DMT1 expression. Cells are then collected after 48 hours of culture in order to use qRT-PCR to find DMT1 expression[2].
|
| References |
| Molecular Formula |
C28H27N7O2
|
|---|---|
| Molecular Weight |
493.57
|
| Exact Mass |
493.222
|
| Elemental Analysis |
C, 68.14; H, 5.51; N, 19.87; O, 6.48
|
| CAS # |
1408064-71-0
|
| Related CAS # |
1408064-71-0
|
| PubChem CID |
57340685
|
| Appearance |
White to gray solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.694
|
| LogP |
2.33
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
37
|
| Complexity |
753
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C([H])=C([H])C([H])=C(C=1[H])N([H])C(/C(/[H])=C(\[H])/C([H])([H])N(C([H])([H])[H])C([H])([H])[H])=O)N([H])C1C([H])=C([H])C(=C([H])C=1[H])N([H])C1=NC([H])=C([H])C(C2=C([H])N=C([H])C([H])=C2[H])=N1
|
| InChi Key |
RADRIIWGHYFWPP-WEVVVXLNSA-N
|
| InChi Code |
InChI=1S/C28H27N7O2/c1-35(2)17-5-9-26(36)31-24-8-3-6-20(18-24)27(37)32-22-10-12-23(13-11-22)33-28-30-16-14-25(34-28)21-7-4-15-29-19-21/h3-16,18-19H,17H2,1-2H3,(H,31,36)(H,32,37)(H,30,33,34)/b9-5+
|
| Chemical Name |
3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
|
| Synonyms |
JNK inhibitor; JNK IN 7; JNK-IN-7; JNKIN7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 33.3~50 mg/mL (67.5~101.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.75 mg/mL (5.57 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0261 mL | 10.1303 mL | 20.2606 mL | |
| 5 mM | 0.4052 mL | 2.0261 mL | 4.0521 mL | |
| 10 mM | 0.2026 mL | 1.0130 mL | 2.0261 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
